ZYBERNO
Stock Report
Updated Sep 2, 2026

Hongchang International Co., Ltd (HCIL)

Healthcare • OTC

$0.10

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
27.0/100
POOR BUSINESS
Hongchang International Co., Ltd (HCIL) scores 27/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
-2.4%
Fairly Priced
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):POOR (6.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.15x)
Operating Margin (Operational Efficiency):GOOD (15.1%)
Return on Capital (Capital Efficiency):POOR (5.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Hongchang International Co., Ltd (HCIL) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, Hongchang International Co., Ltd (HCIL) shows a Brina Gap of -2.4%, which weakens the case: based on the company's ROIC (5.0%) and reinvestment rate (176.0%), the business can fundamentally grow at 8.8% — but the current enterprise value implies the market expects 11.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.10
Market Cap:$51.94M

Valuation Multiples (4)

P/B Ratio:1.19x
P/S Ratio:2.85x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$59.11M
Ev Ebitda Ratio:19.21x

Price Action & Momentum (1)

% of 52-Week High:39.8%
B. Profitability Assessment

Return Metrics (7)

ROA:4.1%
Reinvestment Rate:176.0%
Fundamental Growth Rate (g):8.8%
Market-Implied Growth Rate:11.2%

Margin Analysis (3)

Operating Margin Ttm:15.1%
Net Margin Ttm:13.7%
Ebitda Margin:16.9%

TTM Performance (3)

Gross Margin Ttm:10.8%
Operating Margin Ttm:15.1%
Net Margin Ttm:13.7%

Yield Metrics (2)

Earnings Yield:$0.51
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:129.7%
Latest Earnings Filed:2026-02-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):100.0%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.85x
Quick Ratio:0.84x
Cash Ratio:0.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.15x
Debt-to-Equity Ratio:0.15x
Debt To Ebitda:2.51x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-1,499,338.00
Cash And Cash Equivalents:551,778.00
Long Term Debt:$6.87M
Net Debt:$7.17M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $18.23M
Linear Growth: 100.0%
📊 Click to view full HCIL Revenue analysis & methodology →
Cost Of Revenue Ttm:$14.48M

Profitability Breakdown (2)

Gross profit TTM: $1.97M
Linear Growth: 100.0%
📊 Click to view full HCIL Gross Profit analysis & methodology →
Operating income TTM: $2.75M
Linear Growth: -50.0%
📊 Click to view full HCIL Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: $2.50M
Linear Growth: -50.0%
📊 Click to view full HCIL Net Income analysis & methodology →
Income Before Tax:$2.75M
Ebitda Ttm:3,077,167.00

Operating Expenses (5)

Operating Expenses:1,001,294.00
R And D Expense:0.00
Sga Expense:997,432.00
Income Tax Expense:$248.51K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:24.8%
Ebitda Margin:16.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$65.88M
Current Assets:$8.18M
Ppe Net:27,862,228.00
Goodwill:0.00
Intangible Assets:$2.99K

Liability Structure (4)

Total Liabilities:22,178,508.00
Current Liabilities:9,679,701.00
Long Term Debt:$6.87M
Short Term Debt:$857.77K

Equity & Capital (3)

Equity:$43.70M
Retained Earnings:$388.86K
Common Stock:2,000,000,000.00

Working Capital Items (3)

Accounts Receivable:5,850,090.00
Inventory:49,536.00
Accounts Payable:154,416.00

Special Items (2)

Contract Liabilities:266.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$1.69M
Linear Growth: 100.0%
-$11.36M

Investment Activities (1)

Investing Cash Flow:-$135.59K

Financing Activities (3)

Financing Cash Flow:-$79.88K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$58.91K

Non-Cash Items (1)

Depreciation Amortization Ttm:326,019.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.00
$0.00
Earnings Per Share Ttm:$0.00

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.04
Operating Cash Flow Per Share:-$0.01

Book Value & Capital (2)

Book Value Per Share:$0.08
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.30x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:3.12x
Days Sales Outstanding Ttm:117.13

Inventory Management (2)

Inventory Turnover Ttm:292.27x
Days Inventory Outstanding Ttm:1.25

Payables & Cash Cycle (2)

Days Payable Outstanding:3.89
Cash Conversion Cycle:114.48
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:176.0%
Fundamental Growth Rate (g):8.8%
Market-Implied Growth Rate:11.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):100.0%
Net Income Growth Rate (Linear):-50.0%
Operating Income Growth Rate (Linear):-50.0%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):100.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):100.0%
Book Value Growth Rate (Linear):5.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:HCIL
Company Name:Hongchang International Co., Ltd
Sector:Healthcare
Industry:Medical Technology
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:518.83M
Shares Outstanding Basic:518.83M
Shares Outstanding Diluted:518.83M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-02 04:30:09 UTC
Data Timestamp:2026-08-24T11:18:25.041277
Scroll to Top